Knight Therapeutics Announces CMED Price Approval of Minjuvi® (tafasitamab) in Brazil

MONTREAL, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltd., has received pricing approval for Minjuvi® (tafasitamab) from the Drugs Market Regulation Chamber (“CMED”). As a result, Knight expects to launch Minjuvi® in Brazil in the second quarter of 2024. In July 2023, ANVISA (Agência Nacional de Vigilância Sanitária) granted Market Authoriz

Related Keywords

Canada ,United States ,Montreal ,Quebec ,Japan ,Brazil ,Portuguesa ,Estado Do Rio ,United Kingdom ,America ,Brazilian ,American ,Morphosys Incyte ,Danielle Le ,Pemigatinib Pemazyre ,Samira Sakhia ,Biotoscana Farma ,Cristiane Coelho ,Drugs Market Regulation Chamber ,United Medical Ltd ,Head Of The Hematology Department ,Incyte Corporation ,Xencor Inc ,Knight Therapeutics Inc ,Drug Administration ,Therapeutics Inc ,Nacional De Vigil ,Market Authorization ,Hematology Department ,Portuguesa Hospital ,Latin America ,Knight Therapeutics President ,Knight Therapeutics Brazil General ,Antibody Dependent Cell Mediated Cytotoxicity ,Antibody Dependent Cellular Phagocytosis ,Prescribing Information ,Region Europe ,Knight Therapeutics ,Latin American ,United Medical ,Response Rate ,Adult Patients ,Incyte ,Diffuse Largeb Cell Lymphoma ,Conditional Approval ,Nited Medical Ltd ,Pharmaceutical Company ,